Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study

PG Richardson; S Bringhen; P Voorhees; T Plesner; UH Mellqvist; B Reeves; C Paba-Prada; HZC Byrne; D Chauhan; K Anderson; E Nordstrom; J Harmenberg; A Palumbo; Pieter Sonneveld

doi:10.1016/s2352-3026(20)30044-2

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study

PG Richardson, S Bringhen, P Voorhees, T Plesner, UH Mellqvist, B Reeves, C Paba-Prada, HZC Byrne, D Chauhan, K Anderson, E Nordstrom, J Harmenberg, A Palumbo, Pieter Sonneveld

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

52 Citations (Scopus)

Original language	English
Pages (from-to)	E395-E407
Journal	Lancet Haematology
Volume	7
Issue number	5
DOIs	https://doi.org/10.1016/s2352-3026(20)30044-2
Publication status	Published - 2020

Access to Document

10.1016/s2352-3026(20)30044-2

Cite this

Richardson, PG., Bringhen, S., Voorhees, P., Plesner, T., Mellqvist, UH., Reeves, B., Paba-Prada, C., Byrne, HZC., Chauhan, D., Anderson, K., Nordstrom, E., Harmenberg, J., Palumbo, A., & Sonneveld, P. (2020). Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematology, 7(5), E395-E407. https://doi.org/10.1016/s2352-3026(20)30044-2

@article{9f407d4cb70d42cbac14a909678c9ca6,

title = "Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study",

author = "PG Richardson and S Bringhen and P Voorhees and T Plesner and UH Mellqvist and B Reeves and C Paba-Prada and HZC Byrne and D Chauhan and K Anderson and E Nordstrom and J Harmenberg and A Palumbo and Pieter Sonneveld",

year = "2020",

doi = "10.1016/s2352-3026(20)30044-2",

language = "English",

volume = "7",

pages = "E395--E407",

journal = "The Lancet Haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "5",

}

Richardson, PG, Bringhen, S, Voorhees, P, Plesner, T, Mellqvist, UH, Reeves, B, Paba-Prada, C, Byrne, HZC, Chauhan, D, Anderson, K, Nordstrom, E, Harmenberg, J, Palumbo, A & Sonneveld, P 2020, 'Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study', Lancet Haematology, vol. 7, no. 5, pp. E395-E407. https://doi.org/10.1016/s2352-3026(20)30044-2

TY - JOUR

T1 - Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study

AU - Richardson, PG

AU - Bringhen, S

AU - Voorhees, P

AU - Plesner, T

AU - Mellqvist, UH

AU - Reeves, B

AU - Paba-Prada, C

AU - Byrne, HZC

AU - Chauhan, D

AU - Anderson, K

AU - Nordstrom, E

AU - Harmenberg, J

AU - Palumbo, A

AU - Sonneveld, Pieter

PY - 2020

Y1 - 2020

U2 - 10.1016/s2352-3026(20)30044-2

DO - 10.1016/s2352-3026(20)30044-2

M3 - Article

VL - 7

SP - E395-E407

JO - The Lancet Haematology

JF - The Lancet Haematology

SN - 2352-3026

IS - 5

ER -